PLX
Protalix BiotherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Elfabrio’s dosing flexibility, partner-led reimbursement expansion, and the $25 million milestone support near-term liquidity and commercial optionality. PRX-115 provides longer-term clinical upside.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
2026 guidance includes the one-time $25 million Chiesi milestone.
Momentum
98
Value
62
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.85 · Bull $4.25 · Bear $1.55
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum98 · Δ7d -
Value62 · Δ7d -0.1
Sentiment66 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
66
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.3 / Value 62.0 / Sentiment 66.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$191.76M
Beta
-0.21
Shares Out
80.57M
P/E (TTM)
38.8
P/S (TTM)
2.33
P/FCF (TTM)
19.47
Rev YoY
+233.7%
EPS YoY
-567.4%
Gross Margin
+70.0%
Op Margin
+10.3%
Net Debt
-$22.65M
Current Ratio
3.15
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology